0000105770 false 0000105770 2025-05-06 2025-05-06

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) – May 6, 2025

WEST PHARMACEUTICAL SERVICES, INC.

(Exact name of registrant as specified in its charter)

Pennsylvania |  | 1-8036 |  | 23-1210010
(State or other jurisdiction of incorporation) |  | (Commission File Number) |  | (IRS Employer Identification No.)
530 Herman O. West Drive, Exton, PA |  |  |  | 19341-1147
(Address of principal executive offices) |  |  |  | (Zip Code)

Registrant’s telephone number, including area code: 610-594-2900

Not Applicable
(Former name or address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol | Name of each exchange on which registered
Common Stock, par value $0.25 per share | WST | New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

1

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
As noted on the original Form 8-K filed on May 8, 2025, the shareholders of the Company approved an amendment and restatement of the 2016 Omnibus Incentive Compensation Plan (the “Plan”). The material provisions of the amendment and restatement of the Plan are described extensively in our definitive proxy statement filed on March 21, 2025 and are qualified in their entirety by the amended and restated Plan attached as an exhibit 10.15 to this Form 8-K/A.
Item 9.01 Financial Statements and Exhibits.

(d) | Exhibit No. | Description
| 10.15 | Amended and Restated 2016 Omnibus Incentive Compensation Plan
| 104 | The cover page from the Company’s Current Report on Form 8-K, dated May 6, 2025, formatted in Inline XBRL.

2

SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

| WEST PHARMACEUTICAL SERVICES, INC.
| /s/ Kimberly Banks MacKay
| Kimberly Banks MacKay
| Senior Vice President, General Counsel and Secretary
May 12, 2025 |

3

EXHIBIT INDEX

Exhibit No. |  | Description
10.15 |  | Amended and Restated 2016 Omnibus Incentive Compensation Plan
104 |  | The cover page from the Company’s Current Report on Form 8-K, dated May 6, 2025, formatted in Inline XBRL.

4